Infectious Disease Clinical Trials Market Report 2026

Infectious Disease Clinical Trials Market Overview

• Infectious Disease Clinical Trials market size has reached to $15.1 billion in 2025 • Expected to grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Rising Healthcare Infrastructure Driving The Growth Of Market Due To Expansion of Medical Facilities and Research Capabilities • Market Trend: New Antibiotic Enters Phase 3 To Combat Deadly Drug-Resistant Bacteria • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the infectious disease clinical trials market include: • Phase III (Segmentation By Phase) → Expected gain of $2.73 Billion • Phase II (Segmentation By Phase) → Expected gain of $1.88 Billion • Phase I (Segmentation By Phase) → Expected gain of $0.98 Billion

What Is Covered Under Infectious Disease Clinical Trials Market?

Infectious disease clinical trials are structured research studies that evaluate the safety, efficacy, and optimal use of drugs, vaccines, or therapies targeting infectious diseases. These trials involve carefully designed protocols to monitor participants’ responses and collect clinical data under controlled conditions. The insights gained help advance medical knowledge and support the development of effective treatments and preventive measures against infectious diseases. The main phases of infectious disease clinical trials are phase I, phase II, phase III, and phase IV. Phase I infectious disease refers to the first phase of clinical trials for a new drug or vaccine, rather than the infection itself. The various indications involved are human immunodeficiency virus, hepatitis, influenza, tuberculosis, malaria, coronavirus disease of 2019 (covid-19), and others, which are studies which randomized controlled trials, open label studies, double blind studies, observational studies, and cohort studies. The various drugs types involved are antibiotics, antivirals, antifungals, vaccines, and combination therapies, which are used by pharmaceutical companies, biotechnology companies, contract research organizations, academic institutes, and others.

What Is The Infectious Disease Clinical Trials Market Growth Forecast?

The infectious disease clinical trials market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing investments in pandemic preparedness, rising use of ai-assisted patient recruitment, expansion of global trial decentralization, growing focus on accelerated regulatory approvals, increasing integration of digital biomarkers. Major trends in the forecast period include increasing adoption of data-driven trial design, rising use of decentralized clinical trial models, growing integration of real-world evidence, expansion of adaptive trial methodologies, enhanced focus on rapid pathogen response.

What Is The Driver Of The Infectious Disease Clinical Trials Market?

The rising healthcare infrastructure is expected to propel the growth of the infectious disease clinical trials market going forward. Healthcare infrastructure refers to the physical facilities, medical equipment, technologies, and trained workforce that support the delivery of healthcare services and enable effective disease prevention, diagnosis, and treatment. Healthcare infrastructure development is rising due to the increasing demand for advanced medical services, the growing burden of emerging and complex diseases, and the need for well-equipped facilities and skilled healthcare professionals to provide timely diagnosis, treatment, and preventive care. Healthcare infrastructure directly supports clinical trial capacity by providing advanced medical facilities, specialized equipment, and enhanced research capabilities essential for conducting comprehensive infectious disease studies. For instance, in January 2025, according to the American Hospital Association, a US-based non-profit organization, total number of hospitals in the United States is projected to reach 6,093 by 2025, reflecting a modest growth in healthcare facilities nationwide. Therefore, the rising healthcare infrastructure is driving the growth of the infectious disease clinical trials industry.

How Will The Drivers Impact Growth In The Global Infectious Disease Clinical Trials Market?

• Increasing Prevalence Of Infectious Diseases (High) – During the forecast period, the increasing prevalence of infectious diseases is expected to become a key growth driver for the infectious disease clinical trials market by 2030. A rising incidence of infectious conditions heightens the demand for new and effective therapies, thereby expanding the need for clinical trials. Greater disease burden creates a broader pool of eligible participants, facilitating faster and more efficient patient recruitment. It also compels pharmaceutical companies to intensify r&d efforts to respond to urgent public health needs. In many cases, governments and global health agencies provide funding and regulatory assistance to combat emerging threats. • Technological Advancements (AI, Genomics, Real-Time Analytics) (Medium) – During the forecast period, technological advancements in ai, genomic sequencing, and real-time analytics are expected to emerge as major drivers of expansion in the infectious disease clinical trials market by 2030. These innovations enhance trial design, optimize patient selection, and improve data monitoring processes. By minimizing errors, strengthening oversight, and accelerating decision-making, such technologies increase trial efficiency and cost-effectiveness while improving outcome reliability. • Government Initiatives Supporting Clinical Trials (Low) – During the forecast period, government initiatives supporting clinical trials are expected to act as a key growth catalyst for the infectious disease clinical trials market by 2030. Governments across the globe are expanding funding programs and implementing supportive policies to advance infectious disease research. Financial incentives, streamlined regulatory pathways, and emergency approval mechanisms help accelerate trial execution. This supportive environment lowers operational barriers for pharmaceutical companies and stimulates increasing clinical trial activity.

How Will The Restraints Impact Growth In The Global Infectious Disease Clinical Trials Market?

• Stringent And Varied Regulatory Requirements (High) – During the forecast period, the different countries impose strict and often inconsistent regulations on clinical trials. These requirements delay approvals, increase administrative burden, and create challenges in managing multi-country studies. As a result, global trial execution becomes costly and time-consuming. • Stringent And Varied Regulatory Requirements (High) – During the forecast period, the different countries impose strict and often inconsistent regulations on clinical trials. These requirements delay approvals, increase administrative burden, and create challenges in managing multi-country studies. As a result, global trial execution becomes costly and time-consuming. • Challenges In Patient Recruitment And Retention For Specific Infectious Diseases (Medium) – During the forecast period, the recruiting eligible patients for trials is difficult, especially for rare infections or diseases concentrated in specific regions. Maintaining patient participation throughout lengthy trial phases is also challenging due to treatment side effects or logistical barriers. Poor recruitment and retention can delay studies and compromise trial outcomes.

Key Players In The Global Infectious Disease Clinical Trials Market

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

Global Infectious Disease Clinical Trials Market Trends and Insights

Major companies operating in the infectious disease clinical trials market are focusing on developing advanced research initiatives, such as phase 3 trials of antibiotic candidates, to help identify rare side effects and confirm optimal dosing. A phase 3 trial of antibiotic candidates is a late-stage study that tests the drug in a large group of patients to evaluate its safety, effectiveness, and how it compares to existing treatments before it can be approved for use. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, launched a Phase 3 clinical trial for zosurabalpin, a novel tethered macrocyclic peptide antibiotic specifically designed to combat CRAB, a critical cause of severe hospital infections worldwide. Zosurabalpin’s unique feature lies in its novel mechanism of action, which blocks the transport of lipopolysaccharide essential for building the bacterial outer membrane, with no resistance reported so far. The global trial will involve approximately 400 patients to evaluate its safety and effectiveness compared to standard treatments. Early research has shown powerful activity against multidrug-resistant bacteria, excellent tolerability, and promising pharmacokinetic properties. This positions Zosurabalpin as a potentially groundbreaking solution in addressing the urgent challenge of antibiotic resistance.

What Are Latest Mergers And Acquisitions In The Infectious Disease Clinical Trials Market?

In February 2025, Flourish Research LLC, a US-based multi-site clinical trial organization, acquired Diablo Clinical Research LLC for an undisclosed amount. With this acquisition, Flourish Research LLC aims to expand its geographic footprint and therapeutic area coverage to strengthen its clinical trial capabilities. Diablo Clinical Research LLC is a US-based company that provides infectious disease clinical trials.

What Defines the Infectious Disease Clinical Trials Market?

The infectious disease clinical trials market consists of revenues earned by entities by providing services such as patient recruitment and enrolment, data collection and management, laboratory testing and analysis, monitoring and safety oversight and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Infectious Disease Clinical Trials Market Report 2026?

The infectious disease clinical trials market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease clinical trials industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.